The Comprehensive Cancer Center of Wake Forest University (CCCWFU) serves a large region in western North Carolina and contiguous regions in six adjoining states. In the last grant period, overall peer-reviewed cancer funding increased from $26 to $31 million (direct) and NCI funding increased from $12.2 to $17.7 million. Our NCI funding has increased 3.5 fold since 2000. Notable achievements include: Interdisciplinary and transdisciplinary interactions: Interprogrammatic and intraprogrammatic publications comprise 22% and 37% of publications in the Cellular Damage and Defense Program (CDD), 24% and 21% of those in the Cell Growth and Survival Program (COS), 22% and 40% in the Cancer Prevention and Control Program (CPC), and 22% and 22% of publications in the Clinical Research Program (CRP). Further, in 67%) of the peer-reviewed research grants in Summary II, CCCWFU principal investigators collaborate with other Cancer Center members as co-investigators or consultants These collaborative efforts are at highest levels since our Cancer Center began collecting these metrics. Innovative translational investigations: From our own preclinical science, we developed a portfolio of therapeutic and imaging clinical investigations. We also initiated nationally prominent programs in prostate cancer genetics, and, using our NCI-funded CCOP research base, led large-scale clinical trials in symptom management. Quality scientific contributions: Whether measured by high impact publications, NCI funding, or indisputably important contributions to cancer science and cancer care, CCCWFU investigators made important contributions to the national cancer effort. Support is requested for Cancer Center Support Grant for Years 37 through 41. The Center has four Programs: Cell Growth and Survival, Cellular Damage and Defense, Clinical Research, and Cancer Prevention and Control. Support is also requested for 9 shared resources: Bioanalytical Laboratory, Biostatistics, Cell and Viral Vector Core Laboratory, Cellular Imaging, Clinical Research Management, Crystallography and Computational Biosciences, Flow Cytometry, Microarray, and Tumor Tissue. For the next funding cycle, we have carefully crafted a strategic plan to reduce the burden of cancer in our region and in the nation.
The Center serves a geographically contiguous, primarily rural area that spans seven states. In this region, the CCCWFU is the primary tertiary center for cancer care. The region has complex racial and ethnic populations that have traditionally not had access to state-of-the-art cancer prevention and treatment. The CCCWFU will not only continue to develop new areas of cancer treatment and prevention, but assure that our region has access to these advances.
|Paek, M-S; Nightingale, C L; Tooze, J A et al. (2018) Contextual and stress process factors associated with head and neck cancer caregivers' physical and psychological well-being. Eur J Cancer Care (Engl) 27:e12833|
|Dutta, Samrat; Rivetti, Claudio; Gassman, Natalie R et al. (2018) Analysis of single, cisplatin-induced DNA bends by atomic force microscopy and simulations. J Mol Recognit 31:e2731|
|Pardee, Timothy S; Anderson, Rebecca G; Pladna, Kristin M et al. (2018) A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res 24:2060-2073|
|Atkins, Hannah M; Appt, Susan E; Taylor, Robert N et al. (2018) Systemic Iron Deficiency in a Nonhuman Primate Model of Endometriosis. Comp Med 68:298-307|
|Godwin, Ryan C; Gmeiner, William H; Salsbury Jr, Freddie R (2018) All-atom molecular dynamics comparison of disease-associated zinc fingers. J Biomol Struct Dyn 36:2581-2594|
|Yang, M; Forbes, M E; Bitting, R L et al. (2018) Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? Ann Oncol 29:311-323|
|Votanopoulos, Konstantinos Ioannis; Bartlett, David; Moran, Brendan et al. (2018) PCI is Not Predictive of Survival After Complete CRS/HIPEC in Peritoneal Dissemination from High-Grade Appendiceal Primaries. Ann Surg Oncol 25:674-678|
|Lamar, Zanetta S; Dothard, Andrew; Kennedy, LeAnne et al. (2018) Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Leuk Lymphoma 59:1871-1877|
|Melvin, Ryan L; Xiao, Jiajie; Berenhaut, Kenneth S et al. (2018) Using correlated motions to determine sufficient sampling times for molecular dynamics. Phys Rev E 98:023307|
|Bhatt, Nikunj B; Pandya, Darpan N; Dezarn, William A et al. (2018) Practical Guidelines for Cerenkov Luminescence Imaging with Clinically Relevant Isotopes. Methods Mol Biol 1790:197-208|
Showing the most recent 10 out of 548 publications